Brii Biosciences Limited BRIBF
Set alert
0.13 USD 0.00 0.00%
At close · Oct 30
0.2312 Day range 0.2459
0.12575 52-week range 0.2459
- YTD
- -30.37%
- 1 year
- -45.97%
- Open
- 0.2459
- Prev close
- 0.13
- Mkt cap
- 93.77M
- Vol
- 4.15K
- Avg vol
- 37
- EPS
- -0.04
- P/E
- 0.00
More statistics
- Low
- 0.2312
- High
- 0.2459
2Y chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 20, 2026 | 5 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 24, 2025 | 10 months ago |
| RSI: Oversold | Dec 24, 2025 | 10 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| MACD: Buy Signal | May 30, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| RSI: Oversold | May 2, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 4, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| RSI: Overbought | Jan 28, 2025 | 1 year ago |
News
- Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript
- Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
- Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
- Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
- Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
- Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
- Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
- Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Your note
Sign in to keep a note on BRIBF — it syncs with the Stock Master app.